Familial Hypertrophic Cardiomyopathy: Late Potentials and Other Prognostic Markers
- PMID: 32042515
- PMCID: PMC6996270
- DOI: 10.7759/cureus.6530
Familial Hypertrophic Cardiomyopathy: Late Potentials and Other Prognostic Markers
Abstract
Familial hypertrophic cardiomyopathy is an autosomal dominant genetic disease considered the most common cause of sudden cardiac death in individuals under 35 years old, especially the athletes. This study aimed to investigate the association between the presence of late potentials and a family history of sudden death, syncope, and complex ventricular arrhythmias on patients with hypertrophic cardiomyopathy. A case series study was carried out from March 2001 to December 2002, including 22 patients with hypertrophic cardiomyopathy according to transthoracic echocardiogram criteria. Patients on a cardiac pacemaker, right bundle branch block, cardiac transplant, and under no possibilities to realize the exams were excluded. The results showed that asymmetric septal hypertrophy was the most common type (73%), 63% had a positive familial history of hypertrophic cardiomyopathy, 55% sudden cardiac death, and 23% syncope. Also, complex ventricular arrhythmias were detected in 14% and late potentials in 23% of patients. According to this study, the presence of late potentials was not associated with familial sudden death, syncope, and complex ventricular arrhythmias.
Keywords: cardiogenic syncope; familial hypertrophic cardiomyopathy; late potentials; prognostic marker; sudden death.
Copyright © 2020, Chaves-Markman et al.
Conflict of interest statement
The authors have declared financial relationships, which are detailed in the next section.
Figures
Similar articles
-
A primer on arrhythmias in patients with hypertrophic cardiomyopathy.Curr Cardiol Rep. 2012 Oct;14(5):552-62. doi: 10.1007/s11886-012-0297-3. Curr Cardiol Rep. 2012. PMID: 22825919 Review.
-
[Sudden cardiac death in familial hypertrophic cardiomyopathy. Identification of high-risk patients].Dtsch Med Wochenschr. 2005 May 6;130(18):1150-4. doi: 10.1055/s-2005-866802. Dtsch Med Wochenschr. 2005. PMID: 15856398 Review. German.
-
Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.Rev Port Cardiol. 2005 Mar;24(3):407-15. Rev Port Cardiol. 2005. PMID: 15929624 English, Portuguese.
-
Arrhythmic Risk Stratification among Patients with Hypertrophic Cardiomyopathy.J Clin Med. 2023 May 10;12(10):3397. doi: 10.3390/jcm12103397. J Clin Med. 2023. PMID: 37240503 Free PMC article. Review.
-
A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy.Circulation. 2020 Jul 21;142(3):217-229. doi: 10.1161/CIRCULATIONAHA.120.047235. Epub 2020 May 18. Circulation. 2020. PMID: 32418493 Free PMC article.
Cited by
-
Prognosis of patients with familial hypertrophic cardiomyopathy: A single-center cohort study with ten-year follow-up by propensity score matching analysis.Heliyon. 2023 Jun 25;9(7):e17629. doi: 10.1016/j.heliyon.2023.e17629. eCollection 2023 Jul. Heliyon. 2023. PMID: 37455958 Free PMC article.
-
Cooperative & competitive binding of anti-myosin tail antibodies revealed by super-resolution microscopy.Arch Biochem Biophys. 2023 Oct 1;747:109753. doi: 10.1016/j.abb.2023.109753. Epub 2023 Sep 14. Arch Biochem Biophys. 2023. PMID: 37714251 Free PMC article.
References
-
- Genetic cardiomyopathies. Wilcox JE, Hershberger RE. Curr Opin Cardiol. 2018;33:354–362. - PubMed
-
- Familial hypertrophic cardiomyopathy - Identification of cause and risk stratification through exome sequencing. Biswas A, Das S, Kapoor M, et al. Gene. 2018;660:151–156. - PubMed
-
- A one health approach to hypertrophic cardiomyopathy. Ueda Y, Stern JA. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612186/ Yale J Biol Med. 2017;90:433–448. - PMC - PubMed
LinkOut - more resources
Full Text Sources